Last edition
News about "Non-Small Cell Lung Cancer (NSCLC) "
Radiopharm Theranostics Begins Enrollment for Third Cohort in Phase 1 Trial of 177Lu-RAD204
Radiopharm Theranostics has opened enrollment for the third cohort of its Phase 1 dose-escalation trial of 177Lu-RAD204, after the Data Safety Monitoring Committee cleared escalation to a 90 mCi dose. Early results from the first two cohorts show tumour uptake and a favourable safety profile.
Non-Small Cell Lung Cancer (NSCLC) | 15/11/2025 | By Dineshwori
Boehringer Ingelheim's Zongertinib Shows 77 Percent Response Rate in HER2-Mutant NSCLC
Boehringer Ingelheim presented Phase Ib Beamion LUNG-1 trial data at ESMO 2025, showing that zongertinib achieved a 77 percent Objective Response Rate (ORR) in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC.
Non-Small Cell Lung Cancer (NSCLC) | 24/10/2025 | By Dineshwori | 144
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy